SAN FRANCISCO and SUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China )
Also on site :
- Legendary Hard Rock Band Racks Up the Heavy Metal as Iconic Album Hits Sales of 20 Million
- 7UP Confirms Return of Limited-Edition Flavor That Once Flew Off Shelves
- 'Days of Our Lives' Alum Has Fans 'Crying' Over Photo During 'Last Father Daughter Dance'